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OBJECTIVE — To examine the relationship between cardiovascular autonomic neuropathy
and pulse waveform analysis (PWA) measures of arterial stiffness in a childhood-onset type 1
diabetes population.
RESEARCH DESIGN AND METHODS — Cardiac autonomic nerve function was mea-
sured in the baseline examination of the Pittsburgh Epidemiology of Diabetes Complications
Study of childhood-onset type 1 diabetes by heart rate variability (R-R interval) during deep
breathing and expressed as expiration-to-inspiration (E/I) ratio. Other cardiovascular and dia-
betesfactorswerealsoassessed.PWAwasperformedusingSphgymoCorPxon144participants
at the 18-year follow-up examination. Univariate and multivariate analyses for associations
between baseline nerve function and other cardiovascular and diabetes-related factors were
performed for augmentation index (AIx), augmentation pressure (AP), and subendocardial
viability ratio (SEVR), a surrogate marker of myocardial perfusion.
RESULTS — E/I ratio correlated negatively with both AIx (r  0.18, P  0.03) and AP (r 
0.32,P0.001)andpositivelywithSEVR(r0.47,P0.001)univariately.Lowerbaseline
E/I ratio, HDL cholesterol, and a history of smoking were associated with higher follow-up (18
years later) AIx and AP and lower SEVR in multivariate analyses. Higher baseline HbA1 was also
associated with higher AP and lower SEVR multivariately.
CONCLUSIONS — Cardiovascular autonomic neuropathy is associated with increased ar-
terial stiffness measures and decreased estimated myocardial perfusion in those with type 1
diabetessome18yearslater.Thisassociationpersistsafteradjustmentforpotentialconfounders
as well as for baseline HbA1, HDL cholesterol, and smoking history, which were also associated
with these PWA measures.
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C
ardiovascular disease occurs earlier
and with greater frequency in peo-
ple with diabetes, a ﬁnding particu-
larly striking in women (1). These
observations are especially true for young
adults with type 1 diabetes, in whom cor-
onary artery disease is increased 10-fold
or greater (2). Much of the risk for coro-
nary artery disease in type 1 diabetes lies
inthepresenceandseverityofatheroscle-
rosis and its risk factors (dyslipidemia/
hyperlipidemia). Blood ﬂow dynamics
and arteriosclerosis or arterial stiffening,
which are measured in a variety of ways,
are also important risk factors for cardio-
vascular events and mortality (3). Inter-
estingly, in case-control studies, arterial
stiffness indexes are shown to be in-
creased generally in those with type 1 di-
abetes (4). Indexes of arterial stiffness can
be measured noninvasively with pulse
waveform analysis (PWA) using applana-
tion tonometry (external application of a
micromanometer-tipped probe over a
peripheralartery)(5).PWAprovidesava-
riety of indexes and hemodynamic pa-
rameters, including 1) augmentation
pressure (AP) and 2) augmentation index
(AIx), both of which provide information
about the effects of early wave reﬂection
on central blood pressure, as well as 3)
subendocardial viability ratio (SEVR), an
indicatorofpotentialformyocardialisch-
emia. SEVR is the ratio of the area under
the time-pressure curve during diastole
(an estimate of myocardial perfusion) to
the area under the curve during systole
(an estimate of cardiac workload) (6).
Currently, few data are available con-
cerning risk factors for increased arterial
stiffness in those with type 1 diabetes. In
addition to traditional cardiovascular dis-
ease risk factors, autonomic neuropathy
(AN),acomplicationoftype1diabetes,is
ofparticularinterest,asitpredictscardio-
vascular events and mortality (7). The au-
tonomicnervoussystemisresponsiblefor
regulating heart rate and vascular tone
and, therefore, may contribute to in-
creasedarterialstiffnessinthosewithtype
1 diabetes. Thus, the aim of the present
study is to examine the association be-
tween cardiovascular autonomic nerve
function and arterial stiffness, via AIx and
AP, and myocardial perfusion, via SEVR,
in a type 1 diabetic population.
RESEARCH DESIGN AND
METHODS— Participants in the
Pittsburgh Epidemiology of Diabetes
Complications (EDC) study, an 18-year
prospective investigation of patients with
childhood-onset (age 17 years) type 1
diabetes, were selected for study. EDC
participants were either diagnosed or
seen within 1 year of diagnosis at Chil-
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1950 and 1980 and were on insulin ther-
apyatinitialdischarge.Baselineexamina-
tion in the EDC study occurred between
1986 and 1988, after which participants
were examined biennially thereafter. At
the 18-year examination (November
2004 to November 2006), PWA was per-
formed.Thestudyprotocolwasapproved
by the University of Pittsburgh Institu-
tional Review Board.
Of the 658 EDC study participants
examined at baseline, 140 (21.3%) had
died by the 18-year follow-up and 79
(12%) had moved out of the area, leaving
439 eligible for examination, 72% of
whom (n  318) took part. For this anal-
ysis, complete data were available for 309
participants. PWA testing began part way
through the 18-year examination period
(January 2006), after which 189 subjects
were seen, 144 (76%) of whom had PWA
performed and formed the study popula-
tion for this analysis.
Physical activity was assessed by sur-
vey as previously described (8). Self-
reported alcohol consumption (average
drinks/week), current and ever-smoker
status (at least 100 cigarettes during life-
time),andmedicationuse(codedaccord-
ing to the World Health Organization’s
Anatomical,Therapeutical,andChemical
Classiﬁcation/Deﬁned Daily Dose [ATC/
DDD] codes) were obtained. Medications
of interest in these analyses were those
potentially effecting pulse wave reﬂection
indexes (i.e., ACE inhibitors, angiotensin
II receptor blockers [ARBs], calcium
channel blockers, -blockers, and ni-
trates) (9). To account for the potential
confounding effect of use of these medi-
cations,adichotomous“pulsewavedrug”
(PWD) variable was created (any use ver-
sus no use).
Systolic and diastolic blood pressure
levels were measured after a 5-min rest
using a random zero sphygmomanome-
ter, according to a standardized protocol.
Hypertension was deﬁned as systolic
blood pressure 130 mmHg or diastolic
blood pressure 80 mmHg or the use of
antihypertensive medication for the pur-
pose of lowering blood pressure. Height
was measured in centimeters and weight
inkilogramsandfromthese,BMIwascal-
culated(kg/m
2).Waistandhipcircumfer-
ences were measured two times (a third
time only if the ﬁrst two measures were
not within 0.5 cm of each other). These
waist and hip measurements were aver-
aged and used to calculate waist-to-hip
ratio. Total cholesterol levels were mea-
sured enzymatically (10). HDL choles-
terol levels were determined using a
modiﬁed (11) precipitation technique
(heparin and manganese chloride) based
on the Lipid Research Clinics method.
Non-HDL cholesterol was calculated by
subtracting HDL cholesterol level from to-
tal cholesterol level. Heart rate response
to deep breathing, the expiration-
inspiration (E/I) ratio, deﬁned cardio-
vascular autonomic neuropathy. In
addition, symptomatic autonomic neu-
ropathyconsistedofbothanabnormalE/I
ratio (1.1) and at least two positive re-
sponses to 21 questions asked during the
EDC physician examination (Diabetes
Control and Complications Trial clinical
protocol) about symptoms of autonomic
neuropathy (e.g., gastroparesis, inconti-
nence, impotence, etc.).
Complete blood counts (CBC) were
determined using the Coulter S-Plus IV
(Beckman Coulter, Fullerton, CA). Uri-
nary and serum creatinine concentrations
were measured using an Ectachem 400
Analyzer (Eastman Kodak, Rochester,
NY). For the ﬁrst 18 months, blood sam-
ples were analyzed for hemoglobin A1
(HbA1) using microcolumn cation-
exchange(Isolab,Akron,OH).Forthere-
mainder of the baseline clinic visits,
automated high-performance liquid
chromatography (Diamat; Bio-Rad, Her-
cules,CA)wasperformed.Thetwoassays
werehighlycorrelated(r0.95;[Diamat
HbA1]  0.18  1.00 [Isolab HbA1]).
Urinaryalbuminwasmeasuredbyimmu-
nonephelometry (12). Albumin excretion
rates (AERs) were calculated using uri-
nary albumin levels from at least two val-
idated timed sample collections.
Aortic AIx, aortic AP, and SEVR were
derived using waveforms measured at the
radial artery using the SphygmoCor Px
version 7.01 (AtCor Medical, Sydney,
Australia). In brief, a high-ﬁdelity micro-
manometer with a frequency response of
2 kHz (Millar Instruments, Houston,
TX) was gently pressed on the right radial
artery until a consistent waveform was
produced. Measurement was stopped af-
ter at least 20 sequential waveforms had
been acquired. Central pressure values
wereestimatedfromradialmeasurements
usingthesoftware’smathematicaltransfer
function, which is both accurate and reli-
able(5).Thepressurewavecreatedbyleft
ventricular contraction propagates for-
ward until meeting sites of resistance that
reﬂectthewavebackward;thus,stifferar-
tery walls result in earlier wave reﬂection
(13). When the reﬂected wave returns
during systole rather than diastole, sys-
tolic pressure is increased or “aug-
mented.” AP is a measure of how much
the early reﬂected wave contributes to
central systolic pressure. AIx represents
thelevelofaugmentationmeasuredandis
expressed as a percentage of the pulse
pressure (PP) (AIx  AP/PP). SEVR is a
tonometric noninvasive measure of myo-
cardial perfusion (as coronary artery per-
fusion takes place primarily during
diastole) relative to cardiac workload
(myocardial contraction). SEVR is mea-
sured as the ratio of the diastolic area un-
der the curve of an arterial pulse wave to
the systolic area under the curve. The
SphygmoCordeviceprovidesaqualityin-
dex, which represents reproducibility of
the waveform. PWA measures with a
quality index 80 were repeated, and
only measures with a quality index 80
were included in this study.
Statistical analysis
Distributionalcharacteristicsandnormal-
ityofallvariableswereassessed.Student’s
t test and one-way ANOVA were used to
compare normally distributed variables
between groups, whereas Mann-Whitney
U and Kruskal-Wallis tests were used for
non-normally distributed variables (e.g.,
AP, triglyceride, serum creatinine, AER,
white blood cell). The 
2 test was used to
compare categorical variables between
groups.
Pearson’s and Spearman’s correla-
tions were used for bivariate correlations
for normal and non-normally distributed
variables, respectively. Linear regression
models were ﬁt for AIx, AP, and SEVR.
All categorical variables were dichoto-
mized, and all continuous variables were
standardized to the sample before multi-
variate regression analyses, to make ap-
propriate comparisons between the PWA
and the remaining 18-year populations.
Modeling of AP required natural logarith-
mically transformed AP [Ln(AP)], since
regression residuals were not normally
distributed. Stepwise forward regression
using baseline variables was completed
for each PWA measure adjusting for con-
currentpotentialconfounders(evenifnot
statistically signiﬁcant). All statistical
analyses were conducted using SPSS 15.0
for Windows (SPSS, Chicago, IL). A min-
imal level of signiﬁcance of P  0.05 is
used. However, due to the limited sample
size, factors with P  0.10 were also con-
sidered important.
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PWA study population (n  144, 46.6%)
andtheremainingEDCpopulationexam-
ined at the 18-year follow-up (nonpartic-
ipants, n  165, 53.4%) are listed in
Table 1. The mean (SD) age and diabe-
tes duration for the PWA population at
baseline were 25.9  7.4 and 17.6  6.7
years, respectively, which did not signiﬁ-
cantly differ from the nonparticipants.
The only signiﬁcantly different factor at
baseline between PWA participants and
nonparticipants was mean baseline heart
rate (76.0  12.3 vs. 73.1  11.1; P 
0.04). At follow-up 18 years later, indi-
viduals with PWA measures still had sig-
niﬁcantly higher mean heart rate than
nonparticipants, as well as lower mean
waist-to-hip ratio and mean AER (data
not shown). PWA participants also had a
borderline signiﬁcantly greater percent-
age of reported current smokers at fol-
low-up (15 vs. 8%, P  0.05) but not
ever-smokers (40 vs. 32%, P  0.13).
They also had greater mean alcoholic
drinks/week(2.66.1vs.1.85.2,P
0.09) than non-PWA EDC participants.
AIx and AP were highly correlated
(r  0.90, P  0.001). Both factors were
also signiﬁcantly correlated with height,
heart rate, and age (P  0.01). SEVR was
not signiﬁcantly correlated with AIx (r 
0.06,P0.49),butwasnegativelycor-
related with AP (r  0.21, P  0.01).
SEVR was also signiﬁcantly negatively
correlated with age (r  0.29, P 
0.001) and heart rate (r  0.67, P 
0.001) and positively correlated with
height (r  0.23, P  0.01). AIx and AP
remained signiﬁcantly correlated with
height after adjustment for sex, but SEVR
did not.
Unadjusted correlations between
PWA measures and baseline variables are
described in Table 2. Baseline E/I ratio,
heart rate, and energy expenditure in
sports activities were all negatively asso-
ciated with AIx and AP and positively as-
sociated with SEVR. This pattern did not
change when individuals with symptom-
atic AN (n  19) were excluded from
analysis(datanotshown).Bothnon-HDL
cholesterol and AER were positively asso-
ciated with AP, but not AIx, and nega-
tivelywithSEVR.BMIwascorrelatedonly
with AIx. AIx and AP were higher and
SEVR was lower in women than in men
(Table 2). This same pattern existed be-
tween individuals with a history of smok-
ing compared with individuals without.
A total of 90 (62.5%) of the 144 PWA
study participants reported medication
usethatisknowntoaffectarterialstiffness
(PWD use). Most (88.9%; n  80) were
usinganACEinhibitorand/oranARB.Of
the 16 participants taking -blockers, 10
(62.5%) were also taking ACE inhibitors/
ARBs. The 13 (of 18) reporting calcium
channel blocker use, and 4 (of 5) partici-
pants reporting nitrate use, were also tak-
ing ACE inhibitors/ARBs.
Inmultivariateanalysesrelatingbase-
Table 1—Baseline characteristics of the Pittsburgh EDC study PWA population compared
with the remaining 18-year follow-up participants
PWA study
population
Remaining 18-year
EDC population
n 144 165
Female (%) 50.7 (73) 52.1 (86)
Age (years) 25.9  7.38 26.7  7.50
Diabetes duration (years) 17.6  6.70 18.7  7.34
E/I ratio 1.14  0.12 1.13  0.12
Symptomatic autonomic neuropathy (%) 14.5 (19) 17.3 (27)
Heart rate (bpm) 76.0  12.3 73.1  11.1*
Systolic blood pressure (mmHg) 111.4  13.1 110.2  12.5
Diastolic blood pressure (mmHg) 71.8  10.1 70.6  10.1
Hypertension (%) 22.2 (32) 19.4 (32)
HbA1 (%) 10.1  1.69 10.1  1.71
Non-HDL cholesterol (mg/dl) 127.2  39.9 128.1  36.7
HDL cholesterol (mg/dl) 54.0  11.0 55.6  14.1
Triglycerides (mg/dl) 72.0 (55.0–101.0) 77.0 (58.3–100.0)
Waist-to-hip ratio 0.82  0.07 0.82  0.07
BMI (kg/m
2) 23.5  3.10 23.4  3.37
Albumin excretion rate (	g/min) 9.76 (6.16–27.2) 12.2 (6.88–67.7)
Serum creatinine (mg/dl) 0.90 (0.70–1.00) 0.80 (0.70–1.00)
White blood cell count (
10
9/l) 5.85 (5.18–7.00) 5.90 (5.20–7.00)
Energy expenditure (kcal/week) 450.0 (0.0–1,256.3) 425.0 (0.0–1,585.6)
Ever-smoker (%) 34.5 (50) 28.0 (46)
Prevalent coronary artery disease (%) 4.2 (6) 3.6 (6)
Data are means  SD, medians (IQR), or % (n) unless otherwise indicated, *P  0.05.
Table2—Correlations(ormeansSD)betweenbaselinefactorsand18-yearfollow-upPWA
measures (AIx, AP, and SEVR)
AIx AP SEVR
E/I ratio 0.18† 0.32‡ 0.47‡
Heart rate (bpm) 0.20† 0.16§ 0.44‡
Systolic blood pressure (mmHg) 0.09 0.03 0.11
Diastolic blood pressure (mmHg) 0.00 0.01 0.03
HbA1 (%) 0.02 0.06 0.12
Non-HDL cholesterol (mg/dl) 0.11 0.15§ 0.16§
HDL cholesterol (mg/dl) 0.10 0.05 0.03
Waist-to-hip ratio 0.04 0.02 0.05
BMI (kg/m
2) 0.19† 0.11 0.12
Albumin excretion rate (	g/min) 0.10 0.19† 0.22
Serum creatinine (mg/dl) 0.11 0.11 0.05
White blood cell count (
10
9/l) 0.11 0.12 0.07
Energy expenditure (kcal/week) 0.28‡ 0.29‡ 0.20†
Males (n  71) 19.4  11.5 7.66  6.36 149.7  29.8
Females (n  73)¶ 26.5  9.18 10.4  6.42 135.8  31.2
Never-smoker (n  93) 22.0  11.5 8.42  6.85 145.8  31.1
Ever-smoker (n  49)# 25.3  9.59 10.3  5.71 135.1  30.6
DataaremeansSDofAIx,AP,andSEVRforcategoricalvariables.†P0.05;‡P0.001;§P0.10;P
0.01. ¶Males compared with females: AIx: P  0.001; AP: P  0.003; SEVR: P  0.01. #Never-smokers
compared with ever-smokers: AIx: P  0.09; AP: P  0.01; SEVR: P  0.05.
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low-up potential confounders (age, sex,
height, heart rate, PWD use), lower E/I
ratio, lower HDL cholesterol, and a his-
tory of smoking were associated with
greater follow-up AIx and Ln(AP) (Table
3). Higher baseline HbA1 was also associ-
ated with higher AP. The baseline factors
associated with decreased SEVR were
lowerE/Iratio,higherHbA1,andhavinga
smoking history. Results were similar
when models were adjusted for ACE in-
hibitors/ARB use instead of PWD use.
However, based on P values, ACE inhibi-
tors/ARB use was more signiﬁcantly re-
latedtoPWAmeasuresthanwasthemore
inclusive PWD use variable (data not
shown).
Insex-adjustedanalyses,E/Iratiowas
related to all three PWA measures. In sex-
stratiﬁed analyses (data not shown), E/I
ratio remained signiﬁcantly associated
with AP and SEVR in females but not in
males.
CONCLUSIONS — The key ﬁnding
in this study is that baseline cardiovascu-
lar autonomic neuropathy (measured by
E/I ratio) strongly correlates with both ar-
terial stiffness (measured by both aug-
mentation index and augmentation
pressure) and reduced estimated myocar-
dial perfusion (measured by SEVR) in
childhood-onset type 1 diabetes some 18
years later. Along with cardiovascular au-
tonomic neuropathy, known cardiovas-
cular risk factors such as reduced HDL
cholesterol and cigarette smoking were
also predictive of the increased stiffness
indexesAIxandAP.Poorerglycemiccon-
trol (higher baseline HbA1) in this popu-
lation was also associated with higher AP
and with lower SEVR. However, because
we did not have PWA measures at base-
line and cannot be certain that these fac-
tors are true predictors of incidence, it
seems likely that cardiovascular auto-
nomic neuropathy may exert a major
pathophysiological role in the develop-
ment of arterial stiffening.
E/I ratio was predictive, multivari-
ately, of both AIx and Ln(AP). This ﬁnd-
ing is consistent with the ﬁnding by
Ahlgren et al. (14) of a signiﬁcant corre-
lation between E/I ratio and aortic stiff-
ness (measured as aortic distensibility
using ultrasonography) in females, but
not in males, with type 1 diabetes. How-
ever,becauseoflimitedsamplesizeinour
study, sex-stratiﬁed analyses are not con-
clusive.Inourtype1diabetespopulation,
diabetic autonomic neuropathy has been
associated with increased all-cause mor-
tality, and speciﬁcally cardiovascular
mortality,aswellasnonfatalcardiovascu-
lar events (7). Cardiovascular autonomic
neuropathy has also been shown to be as-
sociatedwithleftventricularhypertrophy
and diastolic dysfunction in type 1 diabe-
tes (15). As arterial stiffness indexes are
shown to contribute to left ventricular di-
astolic dysfunction (16), arterial stiffness
may be a critical link between AN and
cardiovascular disease. Type 1 diabetic
patients without neuropathy, nephropa-
thy, or retinopathy have been observed to
have preserved vascular function (17),
which suggests an intimate relationship
between vascular dysfunction and these
complications.
Lower HDL cholesterol, a tradi-
tional cardiovascular risk factor but not
higher non-HDL cholesterol, was inde-
pendentlypredictiveofAIxandLn(AP).
Inastudyofhealthysubjects,Duprezet
al. (18) showed that low HDL choles-
terol was signiﬁcantly correlated to AP
and AIx in women but not in men.
However, the study examined only uni-
variate correlations. The results of the
present study are generally consistent
with baseline HDL cholesterol being as-
sociated with both AIx and Ln(AP) in
partial correlations and in multivariate
sex-adjusted models; in sex-stratiﬁed
analyses, lower HDL cholesterol re-
mained signiﬁcantly associated with
higherAIxandhigherAPinwomenand
with higher AP in men.
Table 3—Baseline predictors of AIx, Ln(AP), and SEVR in multivariate linear regression analysis after potential confounder adjustment
Base model
AIx Ln(AP) SEVR
 SEM Pr
2  SEM Pr
2  SEM Pr
2
Concurrent age 0.19 0.08 0.02 0.07 0.01 0.001 0.29 0.07 0.001
Concurrent heart rate 0.43 0.07 0.001 0.06 0.01 0.001 0.67 0.06 0.001
Female sex 0.49 0.19 0.01 0.07 0.03 0.03 0.38 0.15 0.001
Concurrent height 0.32 0.09 0.001 0.04 0.02 0.01 — — —
PWD use 0.29 0.14 0.04 0.04 0.03 0.05 0.08 0.12 0.52
Base model (r
2) 0.41 0.37 0.60
Multivariate model
AIx Ln(AP) SEVR
 SEM P r
2  SEM P r
2  SEM P r
2
HDL cholesterol 0.24 0.07 0.001 0.05 0.05 0.01 0.001 0.05 — — — —
E/I ratio 0.17 0.08 0.04 0.02 0.04 0.03 0.02 0.05 0.13 0.07 0.06 0.01
Ever-smoker 0.25 0.14 0.07 0.01 0.02 0.05 0.02 0.04 0.41 0.11 0.001 0.05
HbA1 — — — — 0.02 0.03 0.01 0.02 0.13 0.06 0.02 0.02
Final model (P, r
2) 0.001 0.49 0.001 0.53 0.001 0.68
Variables are standardized to the population: (variable  mean)/SD. Base models with concurrent age, sex, height, heart rate, and PWD use (i.e., medications with
potential effect on PWA measures, such as ACE inhibitor, ARB, calcium channel blocker, -blocker, and/or nitrate use). Baseline variables available for forward
regression:systolicbloodpressure,diastolicbloodpressure,non-HDLcholesterol,HDLcholesterol,whitebloodcellcount,albuminexcretionrate,serumcreatinine,
HbA1, BMI, waist-to-hip ratio, energy expenditure in sports at baseline, and E/I ratio.
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associated with all three outcomes. This
ﬁnding is not surprising, since cigarette
smoking is known to be associated with
arterial stiffness indexes, particularly in
individuals with hypertension (19). A
higher baseline HbA1 was also associated
with increased AP and decreased SEVR in
the present study. This is consistent with
the notion that the formation of advanced
glycation end products (AGEs) is one of
theprimarymechanismsinvolvedinarte-
rial stiffening, especially in individuals
with diabetes. Arterial wall exposure to
AGEs can cause cross-linking of collagen
molecules, which in turn reduces arterial
elasticity (20). AGEs are shown to be as-
sociated with increased arterial AIx in in-
dividualswithhypertension(21).Schram
et al. (22) showed that AGEs, speciﬁcally,
pentosidine, Nepsilon-(carboxymethyl)
lysine, and Nepsilon-(carboxyethyl)lysine,
were all signiﬁcantly associated with in-
creased pulse pressure in individuals with
type 1 diabetes cross-sectionally, whereas
A1C was not. However, Gordin et al. (23)
did ﬁnd a concurrent association between
A1C and AIx in a small study of 22 healthy
males with type 1 diabetes. In our study,
concurrent A1C also was not signiﬁcantly
associated with PWA measures (data not
shown). Baseline HbA1 level may better
representthehistoricexposuretohypergly-
cemiathatleadstoAGEexposurethancon-
current A1C.
Many of the factors associated with
AIx were also associated with AP in this
study. This is not surprising, since AIx is
merelyAP/PP
100.APisthemeasureof
contribution that the wave reﬂection
makes to the systolic arterial pressure,
and it is obtained by measuring the re-
ﬂected wave coming from the periphery
to the center. As the reﬂected wave re-
turnsearlierinthecardiaccycle,thereisa
disproportionate rise in systolic blood
pressure and therefore an increase in PP.
It has been shown that AIx increases with
age in the healthy population until 55
years of age, when diastolic blood pres-
sure may plateau or fall, contributing to
higherPP.AP,however,steadilyincreases
with age without reaching a plateau
(24); thus, AP may be a better represen-
tation of vascular aging when PP rises,
since this will result in lower AIx. This
may be true in individuals with type 1
diabetes at a younger age, since type 1
diabetes is associated with accelerated
vascular aging (25). Because poorer gly-
cemic control is also associated with in-
creased PP (22), this may explain why
baseline HbA1 was associated multiva-
riately with AP, but not with AIx.
While nearly half (48.6%) of our
studypopulationshowedevidenceofcar-
diovascular autonomic neuropathy (E/I
ratio 1.1) on exam at baseline, a much
smaller proportion of the population
(14.5%) was experiencing symptomatic
autonomic neuropathy at baseline. Also,
at baseline, no objective measures of au-
tonomic neuropathy in other end-organs
were obtained (e.g., gastroparesis, im-
pairedbladderfunction,impotence,etc.).
Because we did not see any difference in
univariate analyses when individuals
with symptomatic autonomic neuropa-
thy were excluded, we hypothesize that
individuals with autonomic neuropathy
are more likely to have increased arte-
rial stiffness irrespective of concomitant
symptoms.
This study has signiﬁcant limitations.
For one, the sample size was relatively
limited, and, as such, P values 0.10
have been reported. However, this study
is the largest to date to assess PWA
measures (AIx, AP, and SEVR) in type 1
diabetes. Also, this study lacks PWA
measurements at baseline. Thus, signiﬁ-
cant factors in this study can only be con-
sidered potential predictors of the arterial
stiffnessindexesmeasuredandneedtobe
conﬁrmed prospectively in a type 1 dia-
betes population, before designation as
true predictors. Another limitation is that
this population is essentially a survivor
population in that those who were either
deceased or unable to attend at the 18-
year follow-up examination because of
poor health may represent individuals
with greater risk for complications and/or
those most affected by increased arterial
stiffness.Also,comparedwithindividuals
at the 18-year follow-up but without
PWA measures, the PWA study group
had signiﬁcantly lower follow-up AER
measures and waist-to-hip ratio and
therefore may represent a healthier seg-
ment of our type 1 diabetes population
(data not shown). However, these limita-
tionsaremorelikelytohinderﬁndingsig-
niﬁcant relationships between baseline
factors and follow-up PWA measures
than demonstrate false relationships.
Furthermore, this is the ﬁrst study to
examinemultiplepotentialriskfactorsfor
arterial stiffness in a type 1 diabetes pop-
ulation. The ﬁndings of this study have
clinicalsigniﬁcance,sinceweshowpoten-
tially modiﬁable risk factor states (notably
cardiovascular autonomic neuropathy, cig-
arette smoking, poor glycemic control, and
low HDL cholesterol levels) are associated
with increased arterial stiffness and lower
estimated myocardial perfusion later in life
in type 1 diabetes. The results of this study
also conﬁrm that the use of antihyperten-
sive medications, speciﬁcally ACE inhibi-
tors/ARBs, is associated with lower arterial
stiffness indexes but does not necessarily
improve coronary artery perfusion. Thus,
early testing and treatment for autonomic
neuropathymaybeeffectiveinreducingar-
terial stiffness and, in turn, cardiovascular
morbidityandmortalityinindividualswith
type 1 diabetes.
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